Ocular Therapeutix
OCUL
154 hedge funds and large institutions have $774M invested in Ocular Therapeutix in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 18 closing their positions.
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
12% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $9.14M
3% more funds holding
Funds holding: 149 → 154 (+5)
4.87% less ownership
Funds ownership: 66.98% → 62.11% (-4.9%)
26% less capital invested
Capital invested by funds: $1.04B → $774M (-$269M)
60% less funds holding in top 10
Funds holding in top 10: 10 → 4 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$8.9M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.36M |
| 3 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
+$7.06M |
| 4 |
BlackRock
New York
|
+$6.83M |
| 5 |
Two Sigma Investments
New York
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$30.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$28.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$18.1M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$17.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$7.66M |
OCUL Hedge Fund Activity: Q1 2021 in Review
154 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2021, worth a combined $774M — down 26% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new OCUL positions and 18 closed out — a net gain of 7 holders — while 55 added to existing stakes and 45 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $8.9M. The largest seller was Versant Venture Management, exiting entirely with an estimated $30.3M sold.
- 154 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2021, up from 149 in Q4 2020.
- Funds reported $774M of Ocular Therapeutix stock for Q1 2021, down 26% quarter-over-quarter.
- 25 funds opened new Ocular Therapeutix positions in Q1 2021 and 18 closed out, a net change of +7 holders.
- The largest Ocular Therapeutix buyer in Q1 2021 was Victory Capital Management, an estimated $8.9M added.
- The largest Ocular Therapeutix seller in Q1 2021 was Versant Venture Management, an estimated $30.3M sold.
Based on aggregated 13F filings for Q1 2021.